Abstract

Background: Hyperesinophilia (HES)with Hereditary angioedema (HAE), is a rare disease characterized by peripheral blood eosinophilia > 1500/mcl (> 1.5 × 109/L) persisting ≥ 6 months and the presence of end-organ damage. Hereditary angioedema is a lifelong illness characterized by recurrent swelling of the skin, intestinal tract, and, the upper airway. It results from insufficient activity of the C1-inhibitor protein, leading to disturbances in the kallikrein/bradykinin pathway. Case presentation: We reviewed a case of Hypereosinophilia with hereditary angioedema (HAE) in 7-year-old boy who was referred from another hospital in Coimbatore for further management. He had elevated absolute eosinophilic count & elevated IgE. Bone marrow aspiration and biopsy were done which showed increased eosinophil. Stool for ova/ cyst was negative. He was initiated on oral prednisolone (10mg), pantaprozole (20mg) & dexamethasone (50mg). Conclusion: Hereditary angioedema (HAE) is a genetic condition that poses a threat to life; this condition necessitates rapid diagnosis and treatment to control acute attacks and avert potentially lethal complications, especially when swelling impacts the airway, and can despite recent developments in treatment options, a child quality of life can be significantly affected.

• 1.   Chen E. Rosenberg MD, Patricia C. Fulkerson MD, PhD , Kelli W. Williams MD, MPH(2022). Diagnosis and Management of Paediatric Hypereosinophilic Syndrome. The Journal of Allergy and Clinical Immunology,10(5). 1131-1138 https://doi.org/10.1016/j.jaip.2022.02.007.
• 2.   Magerl M, Gothe H, Krupka S, Lachmann A. (2020). A Germany-wide survey study on the patient journey of patients with hereditary angioedema. Orphanet J Rare Dis. 15(1). 221-229.
• 3.   Maurer M, Magerl M. (2021). Differences and similarities in the mechanisms and clinical expression of bradykinin-mediated vs. Mast cell– mediated angioedema. Clin Rev Allergy Immunol. 61(1). 40-49.
• 4.   Schwartz JT, Fulkerson PC. (2018). An Approach to the Evaluation of Persistent Hyper
• 5.   eosinophilia in Pediatric Patients. Front Immunol9(2). 1944.
• 6.   William Shomali,Jason Gotlib (2021). World Health Organization-defined eosinophilic disorders: 2021 update on diagnosis, risk stratification, and management. Am J Hematol 2021; 97(10): 1243-1259.American Journal of Hematology 97(10). DOI:10.1002/ajh.26352.
• 7.   Burris D, Rosenberg CE, Schwartz JT, et al (2019). Paediatric hyper eosinophilia: characteristics, clinical manifestations, and diagnoses. J Allergy ClinImmunolPract.7(8) .2750- 2758.
• 8.   Maurer M, Magerl M, Ansotegui I, AygorenPursun E, Betschel S, Bork K, Bowen T et al (2018) The international WAO/EAACI guideline for the management of hereditary angioedema-The 2017 revision and update. Allergy 73:1575–1596
• 9.   Roufosse F, Kahn J-E, Rothenberg ME, Wardlaw AJ, Klion AD, Kirby SY, Gilson MJ, Bentley JH, Bradford ES, Yancey SW, Steinfeld J, Gleich GJ. (2020), Efficacy and safety of mepolizumab in hypereosinophilic syndrome: a Phase III, randomized, placebo-controlled trial, Journal of Allergy and Clinical Immunology , doi: https://doi. org/10.1016/j.jaci.2020.08.037
• 10.   Herández-Benítez R, Vicencio-Rivas J, IglesiasLeboreiro J, Martina-Luna M, Madrazo-Miranda MR, Lases-RufeilS(2019). Hypereosinophilic syndrome in an infant. Bol Med Hosp Infant Mex. 76:134-137.
• 11.   Kristine AppelUldall Pallesen, TroelsHerlin, Mette Holm, Christian Høst, Mette Christiansen, MetteRamsing, MadsKirchheiner Rasmussen, MetteSommerlund (2020).Idiopathic hypereosinophilic syndrome: A rare diagnosis in children.Clin Case Rep..8(10): 2013–2016.

Data Sharing Statement

Funding